Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating, rare
disease associated with high mortality. ATTR-CM occurs when TTR amyloid protein builds …

Transthyretin cardiac amyloidosis (ATTR‐CA) demonstrates progressive, potentially fatal,
and infiltrative cardiomyopathy caused by extracellular deposition of transthyretin‐derived …

Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy
caused by extracellular deposition of transthyretin, normally involved in the transportation of …

Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart
failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the …

Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-recognized and
underdiagnosed disease. Although traditionally considered a rare condition, the …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

BACKGROUND: TRACS sought to describe the clinical outcomes and disease progression
of transthyretin (TTR) cardiac amyloidosis (ATTR) in an observational study. Clinical course …

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a life‐threatening condition with a
heterogeneous clinical presentation. The recent availability of treatment for ATTR‐CM has …

Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is predominantly diagnosed in
men. The few available studies suggest affected women have a more favourable cardiac …